140 related articles for article (PubMed ID: 20363214)
21. Urocortin: a cardiac protective peptide?
Tao J; Li S
Biochem Biophys Res Commun; 2005 Jul; 332(4):923-6. PubMed ID: 15949465
[TBL] [Abstract][Full Text] [Related]
22. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure.
Rademaker MT; Cameron VA; Charles CJ; Richards AM
Eur Heart J; 2006 Sep; 27(17):2088-98. PubMed ID: 16825287
[TBL] [Abstract][Full Text] [Related]
23. Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A.
Yang LZ; Kockskämper J; Heinzel FR; Hauber M; Walther S; Spiess J; Pieske B
Cardiovasc Res; 2006 Feb; 69(2):402-11. PubMed ID: 16386238
[TBL] [Abstract][Full Text] [Related]
24. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors.
Suda T; Kageyama K; Sakihara S; Nigawara T
Peptides; 2004 Oct; 25(10):1689-701. PubMed ID: 15476936
[TBL] [Abstract][Full Text] [Related]
25. Modulation of corticotropin-releasing hormone type 2 receptor and urocortin 1 and urocortin 2 mRNA expression in the cardiovascular system of prairie voles following acute or chronic stress.
Pournajafi-Nazarloo H; Partoo L; Sanzenbacher L; Azizi F; Carter CS
Neuroendocrinology; 2007; 86(1):17-25. PubMed ID: 17551267
[TBL] [Abstract][Full Text] [Related]
26. Urocortins as cardiovascular peptides.
Takahashi K; Totsune K; Murakami O; Shibahara S
Peptides; 2004 Oct; 25(10):1723-31. PubMed ID: 15476939
[TBL] [Abstract][Full Text] [Related]
27. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep.
Charles CJ; Jardine DL; Rademaker MT; Richards AM
J Endocrinol; 2010 Feb; 204(2):181-9. PubMed ID: 19914944
[TBL] [Abstract][Full Text] [Related]
28. [Biomarkers in heart failure: BNP and NT-proBNP].
Ho CC; Liu CC
Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
[TBL] [Abstract][Full Text] [Related]
29. Urocortin and cardiovascular protection.
Huang Y; Yao XQ; Lau CW; Chan YC; Tsang SY; Chan FL
Acta Pharmacol Sin; 2004 Mar; 25(3):257-65. PubMed ID: 15000874
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure.
Tang WH; Shrestha K; Martin MG; Borowski AG; Jasper S; Yandle TG; Richards AM; Klein AL; Troughton RW
J Card Fail; 2010 Aug; 16(8):635-40. PubMed ID: 20670842
[TBL] [Abstract][Full Text] [Related]
31. Urocortin: advancing the neurohumoral hypothesis of heart failure.
Burnett JC
Circulation; 2005 Dec; 112(23):3544-6. PubMed ID: 16330694
[No Abstract] [Full Text] [Related]
32. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure.
Davis ME; Pemberton CJ; Yandle TG; Lainchbury JG; Rademaker MT; Nicholls MG; Frampton CM; Richards AM
Clin Sci (Lond); 2005 Oct; 109(4):381-8. PubMed ID: 15882144
[TBL] [Abstract][Full Text] [Related]
33. N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.
O'Donoghue M; Januzzi JL
Expert Rev Cardiovasc Ther; 2005 May; 3(3):487-96. PubMed ID: 15889976
[TBL] [Abstract][Full Text] [Related]
34. Newer biomarkers in heart failure.
Gupta S; Drazner MH; de Lemos JA
Heart Fail Clin; 2009 Oct; 5(4):579-88. PubMed ID: 19631181
[TBL] [Abstract][Full Text] [Related]
35. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential.
Japp AG; Newby DE
Biochem Pharmacol; 2008 May; 75(10):1882-92. PubMed ID: 18272138
[TBL] [Abstract][Full Text] [Related]
36. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands.
Krause K; Schnitger A; Fimmel S; Glass E; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):166-70. PubMed ID: 17326013
[TBL] [Abstract][Full Text] [Related]
37. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
[TBL] [Abstract][Full Text] [Related]
38. What we may expect from biomarkers in heart failure.
Richards AM
Heart Fail Clin; 2009 Oct; 5(4):463-70. PubMed ID: 19631172
[TBL] [Abstract][Full Text] [Related]
39. [Clinical differences between heart failure versus ischemic patients].
Pinelli M; Bindi M; Moroni F; Rosada J; Castiglioni M
Recenti Prog Med; 2007; 98(7-8):378-83. PubMed ID: 17685185
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of action and clinical implications of cardiac urocortin: a journey from the heart to the systemic circulation, with a stopover in the mitochondria.
Kuizon E; Pearce EG; Bailey SG; Chen-Scarabelli C; Yuan Z; Abounit K; McCauley RB; Saravolatz L; Faggian G; Mazzucco A; Townsend PA; Scarabelli TM
Int J Cardiol; 2009 Nov; 137(3):189-94. PubMed ID: 19406492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
